90 results about "Live virus" patented technology

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.

The invention discloses a PDCoV-S1 recombinant protein antigen as well as a preparation method and a vaccine thereof, and belongs to the technical field of recombinant protein vaccines. The amino acid sequence of the PDCoV-S1 recombinant protein antigen disclosed by the invention is as shown in SEQ ID NO: 1; the nucleotide sequence of the PDCoV-S1 recombinant protein antigen is as shown in SEQ ID NO: 2. The vaccine provided by the invention only contains recombinant PDCoV-S1 protein and does not contain genetic materials of viruses, so that all risks of virus replication, virulence reversion or gene recombination are fundamentally avoided. Live viruses do not need to be operated in the production process, so that the biological safety risk and the requirement on the production environment are greatly reduced. The constructed stable CHO engineering cell strain is combined with a serum-free suspension culture technology, so that high-density, large-scale and standardized production of the PDCoV-S1 protein can be realized in a bioreactor. The production process is stable and reliable, the batch-to-batch consistency is good, and the uncertainty and volatility caused by the virus culture link of the traditional vaccine are overcome.

This invention relates to the field of plant extract application technology, particularly to banana fruit extract and its applications. This invention reveals that banana fruit extract exhibits excellent performance in relieving inflammation, anti-oxidation, scavenging free radicals, delaying cell aging, inhibiting viruses and bacteria (inactivating HPV, Staphylococcus aureus, Candida albicans, Escherichia coli, and Propionibacterium acnes), reducing infection, promoting cell regeneration and repair, promoting collagen synthesis, enhancing elasticity and firmness, and acting as a plant-derived immunomodulator. Furthermore, it serves as a natural, intelligent transdermal carrier. Safe and non-irritating, this extraction method has shown excellent application value in high-value plants such as saffron, rose, Dendrobium officinale, ginseng, and Ganoderma lucidum. It provides a comprehensive solution for skin from defense to regeneration, offering a regulatory-compliant natural solution for functional skincare.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The present application relates to the field of biological medicine, in particular to a kind of muscone in the application of viral inhibitor.The viral inhibitor of the present application is used to inhibit the replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus.The present application finds that muscone has no cytotoxicity, and does not directly inactivate virus, but produces antiviral effect on Japanese encephalitis virus by inhibiting NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and other signal pathways, and inhibits porcine epidemic diarrhea virus invasion into cells by reducing caveolin level.The antiviral effect is remarkable, the mechanism of action is clear, the selectivity is high, and the safety is better.

The present invention relates to methods of viral inactivation with a mixture of solvent and detergent. In particular, the present invention is directed to a method for preparing a virus-inactivated polypeptide solution wherein a polypeptide material is first loaded into an affinity chromatography column then incubated with said mixture of a solvent and a detergent within the affinity chromatography column.

The application relates to a method for inactivating viruses in sewage. The method comprises the following steps: introducing heterotrophic bacteria into sewage to be inactivated; increasing the carbon-nitrogen ratio of the sewage during the activation and expansion of the heterotrophic bacteria; washing and resuspending the activated and expanded heterotrophic bacteria to form a heterotrophic bacteria liquid to be used; inoculating the heterotrophic bacteria liquid into the sewage and reducing the carbon-nitrogen ratio of the sewage, so that the heterotrophic bacteria produce an oxidative stress response to inactivate viruses. The method adjusts the carbon-nitrogen ratio to make the heterotrophic bacteria change from an eutrophic environment to an oligotrophic environment, activates the oxidative stress pathway of the heterotrophic bacteria, increases the generation of oxidative active species such as superoxide free radicals, causes oxidative damage to the virus shell or envelope, and thus promotes the inactivation of viruses. The method is simple and efficient, and has a wide application scenario.

The application discloses a kind of RNA virus nucleic acid preservative in fecal sample, including denaturant, chelating agent, pH buffering agent, osmotic pressure regulator and reducing agent;The denaturant includes guanidine salt and surfactant;The application further additionally provides a kind of RNA virus nucleic acid preservative in fecal sample preparation method, preparation above-mentioned one kind of RNA virus nucleic acid preservative in fecal sample, including the following steps: each component is mixed with ratio, pH is adjusted with pH buffering agent, with deionized water constant volume;Filter, obtain the preservative solution described in this application.The preservative solution of the application can stably store human cell DNA and viral RNA in fecal sample at room temperature for at least 7 days, which is beneficial for long-distance transportation at room temperature;Meanwhile, the preservative solution of the application also releases nucleic acid, inactivates virus, so as to prevent biological leakage and infection phenomenon;The de-inhibitor component in the preservative solution can directly combine and precipitate with various inhibitors in feces, reducing the interference to nucleic acid detection.

The invention discloses an HPV virus inactivation dressing and a preparation method thereof, and relates to the field of HPV virus inactivation dressings, the HPV virus inactivation dressing comprises, by weight, 50-90 parts of animal extract, 5-15 parts of morchella, 5-10 parts of sodium carboxymethyl cellulose, 5-10 parts of gelatin and 30-35 parts of purified water. Through the synergistic effect of the animal extract, the morchella esculenta and special substances, HPV viruses can be efficiently inactivated, and the detergent has sterilization and anti-inflammation effects and is suitable for various detergent products; through the synergistic effect of the animal extract and the morchella esculenta, the HPV virus can be efficiently inactivated, and experimental results show that the inactivation rates of HPV16 type pseudoviruses and HPV18 type pseudoviruses reach 90.53% and 98.79% respectively.

This invention provides a method for purifying high-purity recombinant follicle-stimulating hormone (FSH). Specifically, it includes the following steps: (a) providing a raw material solution containing recombinant FSH; (b) sequentially subjecting the raw material solution to: (b1) ammonium sulfate precipitation; (b2) hydrophobic interaction chromatography (HIC); (b3) low pH incubation to inactivate the virus; and (b4) reversed-phase chromatography (RPC); wherein steps (b1), (b2), (b3), and (b4) cannot be performed in any arbitrary order. Compared with existing preparation methods, the recombinant FSH obtained by the method of this invention is simpler and easier to operate, and the purity of the recombinant FSH obtained by the method of this invention can reach up to 99.5% w / w, with a specific activity as high as 16000 IU / mg.

A nucleic acid construct encoding a plurality of polypeptide antigens or immunogens or other polypeptides of interest. The constructs express proteins comprising immunogenic or antigenic sequences of two, three or more polypeptides of interest. Once expressed by the nucleic acid construct, the protein is processed by cleaving the N-terminal signal peptide and cleaving the 6K, 6K-like or internal signal peptide cleavage site to release each polypeptide of interest. Vectors comprising the constructs can be used to deliver them to subjects in need of vaccination, the vectors comprising a replicon and a live viral vector. Vaccines and methods of treatment using the nucleic acid constructs are also described.

The application discloses a method for constructing a cell membrane fusion model induced by a novel coronavirus-like particle, and belongs to the technical field of biology. The method comprises the following steps: constructing a virus-like particle containing a SARS-CoV-2 spike protein gene and an RNA packaging sequence PS9, using HEK-293T cells as packaging cells, co-expressing structural proteins M, E, N and S protein, and realizing assembly of VLPs without replication ability. Subsequently, the VLPs are used to infect immortalized type II alveolar epithelial cells, S protein expression is induced and cell-cell membrane fusion is mediated without the need of BSL-3 laboratory conditions. The formation of fused giant cells can be directly observed through ZO-1 protein immunofluorescence staining, the model is stable, has high biological safety, and is repeatable in vitro. The application overcomes the safety risk of live virus infection and the authenticity problem of a transient transfection model, can be used for research on a SARS-CoV-2 virus membrane fusion mechanism, and has a good application prospect.

The present invention discloses a broad-spectrum influenza vaccine antigen fragment, recombinant probiotics and applications. The present invention utilizes the high conservation of the M2e sequence in different subtypes of influenza viruses and is expected to develop into a broad-spectrum influenza vaccine with cross-protection efficacy. The probiotic Escherichia coli EcN is used to express and secrete the 5M2e antigen. The vaccine preparation process does not involve live viruses. Compared with the traditional chicken embryo influenza vaccine preparation method, the operation is safer and simpler, and it is suitable for rapid large-scale production. The vaccine of the present invention can be immunized by nasal drops. Compared with the commonly used intramuscular injection immunization route, it is safer and simpler to use, and is closer to the natural invasion route of influenza viruses into the host, which is conducive to inducing mucosal immune responses.

The invention relates to the technical field of biomedical materials, in particular to polynucleotide / macromolecular protein composite gel capable of tolerating terminal moist heat sterilization as well as a preparation method and application of the polynucleotide / macromolecular protein composite gel. The product provided by the invention is a composite gel of polynucleotide PN and a specific type of high-molecular protein, and under the conditions of a specific ratio and molecular weight, the high-thermal denaturation temperature is higher, and the high-molecular protein with a specific structure has a better protection effect on the polynucleotide PN; the stability and biological activity of polynucleotide PN molecules can be kept under the condition of high-temperature terminal sterilization, the safety of a sterilized product can achieve the effect of thoroughly inactivating viruses, and the filling and supporting properties of the product serving as a stent material are completely reserved; the compound can be directly used in drugs, medical instruments or cosmetics in the field of tissue engineering, and has high safety and lasting effect.

The invention provides a virus inactivation method of a liquid biological product, which adopts a virus inactivation device to carry out virus inactivation on the liquid biological product, and the virus inactivation device comprises a box body, a console, an overflowing container arranged in the box body and an ultraviolet lamp group arranged in the box body, a liquid biological product is continuously introduced into the liquid inlet buffer bin through the peristaltic pump, upwards overflows through the liquid inlet buffer bin, enters the temporary liquid storage bin after passing through the plurality of quartz round tubes, and is finally discharged from the second flow guide silicone tube; the liquid biological product is irradiated by the first ultraviolet lamp and the second ultraviolet lamp to inactivate viruses in the process of flowing in the quartz round tubes. According to the invention, the virus inactivation effect can be improved while the biological activity of the liquid biological product is ensured, and continuous and stable virus inactivation of the liquid biological product can be realized. The virus inactivation device is easy to clean and maintain and long in service life, and the virus inactivation method based on the virus inactivation device is more economical, simpler and more convenient and suitable for large-scale treatment of liquid biological products.

The application belongs to the technical field of biological medicine, and provides a photosensitizer, a targeted delivery nano platform and application. A preparation method of the photosensitizer comprises the following process: a Suzuki coupling reaction is used to synthesize an intermediate with an aldehyde group by taking a brominated or iodinated triphenylamine as a precursor and reacting with boric acid, and then a Knoevenagel condensation reaction is used to convert the terminal aldehyde group into a strong electron-withdrawing dicyanovinyl group by reacting the aldehyde group intermediate with malononitrile, so as to synthesize the photosensitizer PSs. The application takes a structure-optimized photosensitizer (used for generating ROS and inactivating viruses) and a STING agonist (used for activating the STING pathway and inducing cell death) as core treatment components, and takes a rabies virus glycoprotein peptide as a active targeting ligand, so that the "PDT-immune" synergistic inactivation of RABV can be realized.

The invention relates to the field of biological medicine, in particular to application of muscone in preparation of a virus inhibitor. The virus inhibitor is used for inhibiting replication of Japanese encephalitis virus and / or porcine epidemic diarrhea virus. It is found that muscone has no cytotoxicity, does not directly inactivate viruses, generates an antiviral effect on Japanese encephalitis viruses by inhibiting signal channels such as NLRP3 / Caspase-1, Caspase-9 / Caspase-3 / Bax / BCL-2, JNK / ERK / P38 and the like, and inhibits porcine epidemic diarrhea viruses from invading cells by reducing the level of litter protein. The antiviral effect is obvious, the action mechanism is clear, the selectivity is high, and the safety is better.

The application provides a modified porous material, a preparation method thereof and application of the modified porous material in killing bacteria / fungi and inactivating viruses in a water body. The modified porous material comprises a porous material and a long carbon chain quaternary ammonium salt; the long carbon chain quaternary ammonium salt is fixed inside the porous material; the long carbon chain quaternary ammonium salt comprises a quaternary ammonium salt containing one and / or two long carbon chains; the long carbon chain comprises C6-C 20 Alkanes, alkenes, alkynes or arenes. When the modified porous material is used to treat a water body, the sterilization and disinfection process is transferred to the pores of the porous material, sterilization and disinfection are achieved, and quaternary ammonium salt molecules are prevented from remaining in the water, causing secondary pollution. In addition, the porous material has strong adsorption capacity, can adsorb microorganisms in the water into the pores, concentrate relatively dispersed microorganisms in the water, improve the sterilization and disinfection efficiency, and reduce the use of quaternary ammonium salt.

The invention discloses a QMC influenza virus seed as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the QMC virus seed, virus passage adaptation and virus seed preparation are carried out synchronously, and the preparation method comprises the following steps: inoculating an MDCK-XF06 cell with a chick embryo source influenza virus, and culturing to obtain a resuscitation generation virus seed; and then inoculating the resuscitation generation virus seeds on the MDCK cells in a manner of adjusting the virus inoculation infection complex number generation by generation, and culturing to obtain P2-generation main seed batch virus seeds and P3-generation working seed batch virus seeds. According to the preparation method disclosed by the invention, the QMC virus seed with remarkable advantages can be obtained, the virus activity is good, the virus titer is high, a large number of live viruses can be efficiently produced, the genetic stability is excellent, and the consistency and effectiveness of product quality are ensured; in addition, the virus seed completely eradicates tumorigenicity risks, is high in safety and lays a solid foundation for subsequent production of safe, efficient and stable vaccine products.

This invention relates to a monoclonal antibody against RSV virus and its application; the monoclonal antibody or its antigen-binding fragment comprises one or more of the following (1) to (2): (1) three heavy chain complementarity-determining regions in the heavy chain variable region as shown in SEQ ID NO:1, and three light chain complementarity-determining regions in the light chain variable region as shown in SEQ ID NO:2; or, (2) three heavy chain complementarity-determining regions in the heavy chain variable region as shown in SEQ ID NO:9, and three light chain complementarity-determining regions in the light chain variable region as shown in SEQ ID NO:10. The antibody or its antigen-binding fragment of this invention can specifically bind to RSV F protein, and has an affinity of 10 for the DS2 antigen. ‑9 M; can highly inhibit RSV live virus infection of target cells, IC 50 The concentration was 1.27 ng / mL, indicating broad application prospects in clinical practice.

A system for improving indoor air quality for shared and confined spaces with people. This allows an improvement in surrounding air quality in indoor spaces and interaction situations with (i) groups of people among themselves (inter-person transmission), (ii) between people and the above-mentioned indoor spaces (confined spaces, buildings and / or airborne and / or overland and / or seaborne passenger transportation systems and / or confined patient transportation systems such as pods / incubators and others similar thereto), and also (iii) for interaction between people and invasive and non-invasive mechanical ventilation systems. The system proposes the use of a system based on fluid mechanics and UV wavelengths for inactivating viruses and bacteria.

The invention discloses a primer probe, a method and application for detecting human coronavirus OC43. The nucleic acid sequence of the primer comprises the sequences as shown in SEQ ID NO. 7 to SEQ ID NO. 8; the nucleic acid sequence of the fluorescent probe comprises a sequence as shown in SEQ ID NO.9. The primer and the fluorescent probe for detecting the human coronavirus OC43 are creatively designed, the human coronavirus OC43 inactivated virus standard substance can be accurately detected by using the primer, the probe and the digital valuing method, the sensitivity is high, and the specificity is strong.

The present invention discloses a CRH PVN The invention relates to a method for constructing a mouse model of liver depression-type breast cancer with neuronal activation and its application, and belongs to the technical field of animal model construction. The method comprises the following steps: (1) injecting 140-160 nl of liquid containing both rAAV-CRH-CRE-WPRE-hGH polyA and chemical genetic activation virus rAAV-hM3D(Gq)-mCherry into the PVN brain region of CRH-IRES-Cre mice, wherein the titers of the two viruses are 2.4-2.6×10 12 pfu; (2) 25-30 days after virus injection, all mice were implanted with breast cancer cells, and CRH was obtained 38-42 days after breast cancer cell inoculation. PVN The method for constructing a mouse model of liver depression type breast cancer with neuron activation is simple to operate and has good repeatability, and can overcome the disadvantage of large individual differences in animals.

The invention discloses a single-domain antibody specifically combined with a Gn protein of a severe fever with thrombocytopenia syndrome virus. Experiments prove that the antibody has strong binding activity to the Gn protein of the severe fever with thrombocytopenia syndrome virus, the neutralizing effect of pseudovirus and live virus is obvious, and the purity is high after the antibody is humanized. The invention can be used for preparing drugs for treating or preventing diseases caused by severe fever with thrombocytopenia syndrome virus infection, and provides a new means for prevention and control of related diseases.

The present application relates to the technical field of biological medicine, and particularly discloses a virus inactivation method and application. The virus inactivation method of the present application uses formaldehyde as an inactivator, and further includes a formaldehyde blocking step after the virus inactivation with formaldehyde. The active ingredients of the blocking agent used in the formaldehyde blocking step are sodium bisulfite and EDTA-2Na, and the mass ratio of the sodium bisulfite and the EDTA-2Na is (3.8-4.2):1. The method of the present application can effectively reduce the toxicity of formaldehyde when formaldehyde is used as an inactivator, and reduce the residual amount of formaldehyde, and is particularly suitable for the inactivation of bovine dermatophilus virus and the blocking of formaldehyde.

The application relates to the field of biological medicine, and discloses a pH response phase transition sulfonic acid liposome for destroying a virus envelope structure as well as a preparation method and application thereof. The liposome is composed of dioleoyl phosphatidyl ethanolamine, (2,3-dioleoyl-propyl)-trimethylammonium chloride, oleic acid, sodium hexadecyl sulfonate and cholesterol. The liposome constructed by the application can neutralize viruses in the form of adhesion and wrapping of viruses in a high-pH environment in the early stage of virus infection, is endocytosed by cells, and is phase transitioned in lysosomes to realize intracellular inactivation of the viruses. In a low-pH microenvironment of inflammatory tissues caused by the late stage of virus infection, the liposome can directly destroy the virus envelope to realize virus inactivation through phase transition outside cells after adhesion of the viruses. Therefore, the liposome can realize effective killing of viruses in the early stage and the late stage of virus infection, has a spectrum antiviral effect, and has a wide application prospect.

The invention discloses application of acridine compounds in preparation of anti-human immunodeficiency virus drugs, and belongs to the field of preparation of antiviral drugs. Experiments find that the compound can significantly improve the latent HIV-1 transcriptional activity in the body of a patient when being used for preparing drugs for treating AIDS, so that the compound can be recognized by anti-retrovirus drugs. Taking HIV-1 latent infection cells as an example, the compound enables the expression quantity of HIV-1 virus genes to be remarkably improved, and has the potential of activating a virus repository. Therefore, the compound has the potential of eliminating the virus latent library in the body of an AIDS patient, and provides a new possibility for functional cure of AIDS.

The invention relates to a cat omega interferon biological activity detection method and a kit. According to the method, a stable reporter cell line is established by constructing a recombinant plasmid containing a cat omega-interferon specific interferon stimulus response element (ISRE) and a reporter gene (such as luciferase) and transfecting CRFK cells. During detection, report cells and a sample to be detected are co-incubated, cat omega-interferon induces report gene expression by activating a JAK-STAT-ISRE signal channel, the expression level is in direct proportion to interferon activity, and the activity can be quantified by detecting a luminescence value (RLU). The method overcomes the defects of long period (3-5 days), complicated operation and subjective result judgment of the traditional cytopathic effect inhibition method, has the advantages of rapidness (about 24 hours), safety (no live virus), objectiveness, accuracy, good repeatability and easiness in high throughput, and is suitable for quality control analysis of cat omega-interferon products.